{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:25Z","timestamp":1787070925510,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>\n                    Two common molecular-targeted drugs used for treating postmenopausal osteoporosis are denosumab (DEN) and romosozumab (ROMO), with the latter being a newly approved drug. The aim of this systematic review and meta-analysis was to compare the efficacy of DEN and ROMO therapy over 12 months for the management of osteoporosis in postmenopausal patients. The percentage increase in bone mineral density (BMD) at the lumbar spine was the primary outcome of interest, while secondary outcomes included bone density changes at the total hip and incidence of clinical or osteoporotic fractures. Two independent reviewers conducted an electronic search on PubMed, Google Scholar, Web of Science, and Cochrane Library until June 2023 to search for randomized controlled trials that studied the clinical efficacy of ROMO or DEN and included those that fulfilled the eligibility criteria. We used Review Manager 5.4 to analyze our data, with an odds ratio for fractures and pooled mean change for BMD. To assess heterogeneity, we used\n                    <jats:italic toggle=\"yes\">I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    and Chi-square\n                    <jats:sup>2<\/jats:sup>\n                    .\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.05 was considered for statistical significance. This review analyzed twelve trials with a total of 22,445 participants. ROMO and DEN were associated with a significant percentage change in BMD. Patients who received ROMO had significantly lower rates of clinical and osteoporotic fractures, but this was not true for those on DEN. Both ROMO and DEN are effective treatments for osteoporosis in postmenopausal women, increasing BMD within a year. A decrease in fracture incidence is more prominent for ROMO therapy.\n                  <\/jats:p>","DOI":"10.4103\/jmh.jmh_108_25","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T13:01:09Z","timestamp":1757077269000},"page":"235-246","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Efficacy and Safety of Romosozumab versus Denosumab for Treatment of Postmenopausal Osteoporosis: A Meta-analysis"],"prefix":"10.4103","volume":"16","author":[{"given":"Manish","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Government Medical College, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Sabharwal","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Acharya Shri Chander College of Medical Sciences and Hospital, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narita","family":"Jamwal","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Acharya Shri Chander College of Medical Sciences and Hospital, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meeta","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, AIIMS, Jammu, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jyoti Gupta Clinic, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"R1-20250908","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20250908","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.3390\/ijerph19052999","article-title":"Prevalence and predictors of osteoporosis and osteopenia in postmenopausal women of Punjab, India","volume":"19","author":"Khinda","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R3-20250908","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women:An Endocrine Society*clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20250908","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"key":"R5-20250908","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40265-019-01072-6","article-title":"Romosozumab:First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"R6-20250908","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1210\/endo.141.12.7840","article-title":"The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated","volume":"141","author":"Gori","year":"2000","journal-title":"Endocrinology"},{"key":"R7-20250908","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"key":"R8-20250908","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporos Int"},{"key":"R9-20250908","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20250908","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"R11-20250908","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1084\/jem.186.12.2075","article-title":"TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor","volume":"186","author":"Wong","year":"1997","journal-title":"J Exp Med"},{"key":"R12-20250908","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-20250908","doi-asserted-by":"crossref","first-page":"dgaa048","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women:An Endocrine Society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250908","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis:A meta-analysis","volume":"66","author":"Lin","year":"2012","journal-title":"Int J Clin Pract"},{"key":"R15-20250908","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1055\/s-0029-1224109","article-title":"Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis:A systematic review and a meta-analysis","volume":"41","author":"Anastasilakis","year":"2009","journal-title":"Horm Metab Res"},{"key":"R16-20250908","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis:A meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric"},{"key":"R17-20250908","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses:The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R18-20250908","first-page":"1","article-title":"Updated guidance for trusted systematic reviews:a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-20250908","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R20-20250908","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"R21-20250908","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass:A randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R22-20250908","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R23-20250908","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R24-20250908","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-20250908","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","article-title":"Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis","volume":"23","author":"Nakamura","year":"2012","journal-title":"Osteoporos Int"},{"key":"R26-20250908","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy:A randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R27-20250908","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy:Efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"R28-20250908","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"R29-20250908","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis:A phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"key":"R30-20250908","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy:A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"R31-20250908","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"R32-20250908","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"R33-20250908","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R34-20250908","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.3350","article-title":"Longitudinal effects of teriparatide or zoledronic acid on bone modeling- and remodeling-based formation in the SHOTZ study","volume":"33","author":"Dempster","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R35-20250908","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/14656566.2016.1176147","article-title":"Treatment needs and current options for postmenopausal osteoporosis","volume":"17","author":"Gennari","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"R36-20250908","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1759720X16670154","article-title":"Bone modeling and remodeling:Potential as therapeutic targets for the treatment of osteoporosis","volume":"8","author":"Langdahl","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R37-20250908","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Sci Rep"},{"key":"R38-20250908","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","article-title":"A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis","volume":"33","author":"Singh","year":"2022","journal-title":"Osteoporos Int"},{"key":"R39-20250908","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.maturitas.2019.08.003","article-title":"Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis:A systematic review and network meta-analysis of randomized controlled trials","volume":"129","author":"Hernandez","year":"2019","journal-title":"Maturitas"},{"key":"R40-20250908","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13018-018-0865-3","article-title":"Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis:A meta-analysis","volume":"13","author":"Wu","year":"2018","journal-title":"J Orthop Surg Res"},{"key":"R41-20250908","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","article-title":"Severely suppressed bone turnover and atypical skeletal fragility","volume":"93","author":"Visekruna","year":"2008","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Mid-life Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jmh.jmh_108_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:59Z","timestamp":1787067539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jmh.jmh_108_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jmh.jmh_108_25","relation":{},"ISSN":["0976-7800","0976-7819"],"issn-type":[{"value":"0976-7800","type":"print"},{"value":"0976-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-05-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}